Previous close | 1.0600 |
Open | 1.0600 |
Bid | 1.1200 x 27000 |
Ask | 1.1300 x 27000 |
Day's range | 1.0520 - 1.1100 |
52-week range | 1.0400 - 4.3500 |
Volume | |
Avg. volume | 6,315,725 |
Market cap | 339.925M |
Beta (5Y monthly) | 2.32 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.4800 |
Earnings date | 03 May 2023 - 08 May 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 5.10 |
Bionano Genomics (NASDAQ: BNGO) appears to be in just that place -- at the start of its growth journey -- and it could be a great way to give your portfolio some additional upside potential. Bionano's claim to fame is its laboratory analyzer device for optical genome mapping, which it calls the Saphyr.
Image source: The Motley Fool. Bionano Genomics (NASDAQ: BNGO)Q4 2022 Earnings CallMar 09, 2023, 4:30 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood day and welcome to the Bionano fourth-quarter and full-year 2022 earnings conference call.
Bionano Genomics, Inc. (BNGO) delivered earnings and revenue surprises of -44.44% and 0.32%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?